Abstract No. 235 CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma

Portal vein tumor thrombus (PVTT) seriously reduces the survival of patients with hepatocellular carcinoma (HCC). CT-guided iodine-125 (125I) brachytherapy has the advantage of a high local control rate and is minimally invasive. This study aims to evaluate the safety and efficacy of 125I brachytherapy for treating PVTT in HCC patients. Thirty-eight patients diagnosed with HCC complicated with PVTT and treated with 125I brachytherapy for PVTT were included in this retrospective study. The local tumor control rate (LTCR), local tumor progression-free survival (LTPFS), and overall survival (OS) were analyzed. Cox proportional hazards regression analysis was performed to identify predictors affecting survival. The LTCR was 78.9% (30/38). The median LTPFS was 11.6 (95% confidence interval [CI]: 6.7, 16.5) months, and the median OS was 14.5 (95% CI: 9.2, 19.7) months. Multivariate Cox analysis showed that age < 60 years (hazard ratio [HR] = 0.362; 95% CI: 0.136, 0.965; P = 0.042), type I+II PVTT (HR = 0.065; 95% CI: 0.019, 0.228; P < 0.001), and tumor diameter < 5 cm (HR = 0.250; 95% CI: 0.084, 0.748; P = 0.013) were significant predictors of OS. There were no serious adverse events (AEs) related to 125I seed implantation during the follow-up period. CT-guided 125I brachytherapy is effective and safe for treating PVTT of HCC, with a high local control rate and no severe AEs. Patients younger than 60 years old with type I+II PVTT and a tumor diameter less than 5 cm have a more favorable OS.